Cytokinetics, Incorporated - Common Stock — Statistiche Finanziarie Trimestrali (NASDAQ:CYTK)

Financials

Flusso di cassa derivante dalle attività operative -65.57 M-131.62 M-128.24 M-107.5 M-142.65 M-145.46 M -523.85 M Flussi di cassa derivanti dalle attività di investimento 110.86 M105.96 M52.88 M-70.98 M-71.19 M145.49 M 56.2 M Liquidità derivante dalle attività di finanziamento 2.38 M4.75 M78.53 M330.47 M110.7 M7.77 M 527.47 M Liquidità libera -65.57 M-131.62 M-128.24 M-107.5 M-142.65 M-145.46 M -523.85 M

Cytokinetics, Incorporated - Common Stock

Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function.

CYTK

Financials

Cytokinetics, Incorporated - Common Stock

Notizie

Cytokinetics, Incorporated (CYTK) Shareholder/Analyst Call Prepared Remarks Transcript

Cytokinetics: Aficamten Has Momentum, But The Stock Is Too Expensive (NASDAQ:CYTK)

Jefferies alza il target su Cytokinetics dopo i risultati del trial

Cytokinetics prezza un’offerta azionaria da $700 milioni a $71 per azione

CYTK Q1 Earnings Match Estimates, Revenues Beat on Myqorzo Launch

Truist alza il target su Cytokinetics dopo dati positivi del trial

RBC Capital alza il target su Cytokinetics grazie al forte lancio

Cytokinetics (CYTK) Reports Q1 Loss, Beats Revenue Estimates

Cytokinetics: risultati del trial ACACIA-HCM e utili in arrivo martedì

Cytokinetics pianifica un’offerta di azioni ordinarie da 650 milioni di dollari

BofA alza il target price su Cytokinetics dopo i risultati del trial ACACIA

Cytokinetics Stock Rallies After Pivotal Heart Disease Study Hits Dual Primary Endpoints - Cytokinetics (